BCAS2 Antibody Catalog # ASC11076

10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

Specification

BCAS2 Antibody - Product Information

Application WB, IHC, IF Primary Accession O75934 Other Accession CAG46834, 49457027 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Isotype IgG Application Notes BCAS2 antibody can be used for detection of BCAS2 by Western blot at 0.5 - 1 µg/mL. Antibody can also be used for immu Western blot analysis of BCAS2 in MCF7 cell nohistochemistry lysate with BCAS2 antibody at (A) 0.5 and (B) starting at 5 1 µg/mL. µg/mL. For immun ofluorescence start at 20 µg/mL.

BCAS2 Antibody - Additional Information

Gene ID 10286 Target/Specificity BCAS2;

Reconstitution & Storage BCAS2 antibody can be stored at 4℃ for Immunohistochemistry of BCAS2 in human three months and -20℃, stable for up to breast carcinoma with BCAS2 antibody at 5 one year. As with all antibodies care should µg/mL. be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Precautions BCAS2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

BCAS2 Antibody - Protein Information

Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

Name BCAS2

Synonyms DAM1 {ECO:0000303|PubMed:10403562}

Function Required for pre-mRNA splicing as component of the activated spliceosome (PubMed:28502770, PubMed:28076346, PubMed:29360106, at 20 µg/mL. PubMed:29301961, BCAS2 Antibody - Background PubMed:30705154). BCAS2 Antibody: BCAS2 was identified Component of the PRP19-CDC5L complex through differential display analysis as an that forms an integral part of the mRNA species that was overexpressed in MCF7 spliceosome and is required for activating and BT-20 breast cancer cell lines. The pre-mRNA splicing. May have a scaffolding chromosomal region containing this gene, role in the spliceosome assembly as it 1p13.3021, is amplified in these cells lines. contacts all other components of the core BCAS2 is a transcriptional cofactor that complex. The PRP19-CDC5L complex may enhances estrogen receptor-mediated gene also play a role in the response to DNA expression, and directly interacts with the damage (DDR). tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein Cellular Location level in the absence of DNA damage. Nucleus. Nucleus, nucleolus Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but Tissue Location causes G2-M arrest in p53-null or -mutant cells; Ubiquitously expressed. this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment BCAS2 Antibody - Protocols of cancer.

Provided below are standard protocols that you BCAS2 Antibody - References may find useful for product applications. Nagasaki K, Maass N, Manabe T, et al. • Western Blot Identification of a novel gene, DAM1, amplified • Blocking Peptides at chromosome 1p13.3-21 region in human • Dot Blot breast cancer cell lines. Cancer Lett.1999; • Immunohistochemistry 140:219-26. • Immunofluorescence Qi C, Zhu YT, Chang J, et al. Potentiation of • Immunoprecipitation estrogen receptor transcriptional activity by • Flow Cytomety breast cancer amplified sequence Biochem. • Cell Culture Biophys. Res. Commun.2005; 328:393-8. Huo PC, Tsao YP, Chang HW, et al. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer

Page 2/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

Res.2009; 69:8877-85.

Page 3/3